Development of an HIV Rev-dependent dual-reporter cell for anti-HIV drug screenin

描述(申请人提供)：艾滋病毒/艾滋病是一种世界性的流行病，影响着4000万人，目前还没有治愈方法。这项拟议的研究是为了开发一种新的报告细胞系，以促进抗HIV新药的发现。这一未来的报告细胞系统将采用REV依赖的慢病毒载体，该载体已被证明对HIV感染具有高度特异性。这一新系统将极大地促进基于细胞的新型药物筛选平台的开发。此外，通过使用两个记者，该系统可以用于多种检测形式，并将服从于高通量的抗逆转录病毒化合物的筛选。 公共卫生相关性：这项NIH R03小型研究计划拨款是为了开发一种新的研究方法，即开发一种新的REV依赖细胞系来筛选抗HIV药物。艾滋病毒感染导致艾滋病，全球约有4000万人受到艾滋病的困扰。这项拟议的研究将促进新疗法的发展。

DESCRIPTION (provided by applicant): HIV/AIDS is a worldwide pandemic afflicting 40 million people, and currently there is no cure. The proposed research is to develop a new reporter cell line to facilitate the discovery of novel anti-HIV drugs. This prospective reporter cell system will employ a Rev-dependent lentiviral vector, which has been shown previously to be highly specific to HIV infection. This novel system will greatly facilitate the development of a novel cell- based drug screening platform. Additionally, by employing two reporters this system can be used in multiple assay formats and would be amenable to high-throughput screens for antiretroviral compounds. PUBLIC HEALTH RELEVANCE: This NIH R03 Small Research Program grant is to develop a new research methodology, namely, the development of a new Rev-dependent cell line to screen for anti-HIV drugs. HIV infection causes AIDS that afflicted approximately 40 million people globally. This proposed research will facilitate the development of new therapeutics.